Answers are grounded in this paper and cite their sources.
In this issue of Blood , Chari et al 1 show that the combination of pomalidomide and dexamethasone with daratumumab induces high rates of deep and durable responses in heavily pretreated myeloma patients.
No takes yet. Share an insight, caveat, or question.
Kastritis et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: